Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
AssigneesInstitut National de la Sante et de la Recherche Medicale, Université Paris Cité, Sorbonne Universite, Centre National De La Recherche Scientifique, Inovarion
InventorsAngélique GOUGELET, Julie SANCEAU, Lucie POUPEL, Sabine COLNOT
Life of this patent
Estimating the term…